Bionano Genomics, Inc. (Nasdaq: BNGO), shares surged 30.08% to $1.73 in the late hours trading session after on December 28, 2020, Bionano Genomics, Inc. (Nasdaq: BNGO), revealed that Praxis Genomics, LLC had been accredited by the College of American Pathologists (CAP), becoming the first CAP-accredited, CLIA-certified diagnostic lab in the U.S. to offer a whole genome testing method with Saphyr.This test is designed to evaluate postnatal patients for constitutional genetic disorders.
Praxis uses optical genome mapping with the Bionano Saphyr Framework as an option in contrast chromosomal microarray and caryotyping approaches (KT), as they are trying to increase the rate of clinical diagnosis for genetic disorder patients.
- 3 Best E-Commerce Stocks to Buy Now
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
Hence, doctors recommend that sequential rounds of analysis are performed using CMA, KT, repeat expansion testing, and exome sequencing until a pathogenic variant has been identified.
This tiered approach is replaced at Praxis with whole genome analysis using OGM with Saphyr for structural variants (SVs) and next-generation sequencing (NGS) for SNVs.